Underdetermination in evidence-based medicine

Journal of Evaluation in Clinical Practice

Volumn 20, Issue 6, 2014, Pages 921-927

  Chin Yee, Benjamin H ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

basic science; clinical research; Duhem Quine thesis; evidence based medicine; philosophy of science; randomized controlled trial; underdetermination

Indexed keywords

ARTICLE; CLINICAL MEDICINE; CLINICAL RESEARCH; CONCEPTUAL FRAMEWORK; EMPIRICISM; EPIDEMIOLOGY; EPISTEMOLOGY; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL RESEARCH; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PHILOSOPHY; PRIORITY JOURNAL; PROBLEM IDENTIFICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); ETHICS; FEMALE; HEALTH CARE QUALITY; KNOWLEDGE; MALE; METHODOLOGY; STANDARDS;

BIOMEDICAL RESEARCH; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; KNOWLEDGE; MALE; PHILOSOPHY, MEDICAL; QUALITY ASSURANCE, HEALTH CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84922956451     PISSN: 13561294     EISSN: 13652753     Source Type: Journal    
DOI: 10.1111/jep.12258     Document Type: Article

References (43)

1. Guyatt, G., Rennie, D., Meade, M., &, Cook, D., (2008) Users' Guides to the Medical Literature: Essentials of Evidence-Based Clinical Practice, 2nd edn. New York: McGraw Hill Professional.
2. Phillips, B., Ball, C., Sackett, D., Badenoch, D., Straus, S., Haynes, B., &, Dawes, M., (1998) Oxford Centre for Evidence-based Medicine Levels of Evidence [Internet] [updated by Jeremy Howick 2009 Mar 1]. Available at: http://www.cebm.net/index.aspx?o=1025 (last accessed 16 February 2014).
3. Sehon, S. R., &, Stanley, D. E., (2003) A philosophical analysis of the evidence-based medicine debate. BMC Health Services Research, 3 (1), 14.
4. Duhem, P., (1906) La théorie physique: son objet, et sa structure. Paris: Chevalier & Rivière.
5. Quine, W. V. O., (1980) Two dogmas of empiricism. In From a Logical Point of View: 9 Logico-Philosophical Essays, pp. 20-46. Cambridge: Harvard University Press.
6. Curd, M., &, Cover, J. A., (1998) Philosophy of Science: The Central Issues. London: WW Norton.
7. Thatcher, N., Chang, A., Parikh, P., et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 366 (9496), 1527-1537.
8. Stewart, D. J., &, Kurzrock, R., (2013) Fool's gold, lost treasures, and the randomized clinical trial. BMC Cancer, 13 (1), 193.
9. Gossec, L., Tubach, F., Dougados, M., &, Ravaud, P., (2007) Reporting of adherence to medication in recent randomized controlled trials of 6 chronic diseases: a systematic literature review. The American Journal of the Medical Sciences, 334 (4), 248-254.
10. Worrall, J., (2002) What evidence in evidence-based medicine? Philosophy of Science, 69 (S3), S316-S330.
11. Bernard, C., (1865) Introduction à l'étude de la médecine expérimentale. Paris: JB Baillière et fils.
12. Kuhn, T. S., (1977) The Essential Tension: Selected Studies in Scientific Tradition and Change. Chicago: University of Chicago Press.
13. Howick, J., (2011) The Philosophy of Evidence-Based Medicine. Chichester: Wiley-Blackwell, BMJ Books.
14. Kim, E. S., Hirsh, V., Mok, T., et al. (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. The Lancet, 372 (9652), 1809-1818.
15. Ashcroft, R., (2002) What is clinical effectiveness? Studies in the History and Philosophy of Biological and Biomedical Sciences, 33 (2), 219-233.
16. Bluhm, R., &, Borgerson, K., (2011) Evidence-based medicine. In Handbook of the Philosophy of Medicine Volume 16: Philosophy of Medicine (eds, D. M. Gabbay, P. Thagard, &, J. Woods,), pp. 203-238. Amsterdam: Elsevier.
17. Marcum, J. A., (2008) An Introductory Philosophy of Medicine: Humanizing Modern Medicine. Dordrecht: Springer.
18. Sackett, D. L., Rosenberg, W. M., Gray, J. A., Haynes, R. B., &, Richardson, W. S., (1996) Evidence based medicine: what it is and what it isn't. BMJ (Clinical Research Ed.), 312 (7023), 71-72.
19. Gavarret, J., (1840) Principes généraux de statistique médicale. Paris: Béchet Jne et Labé.
20. Thompson, R. P., (2010) Causality, mathematical models and statistical association: dismantling evidence-based medicine. Journal of Evaluation in Clinical Practice, 16 (2), 267-275.
21. Kelton, J. G., Hirsh, J., &, Carter, C. J., (1978) Sex differences in the antithrombotic effects of aspirin. Blood, 52 (5), 1073-1076.
22. Kelton, J. G., Carter, C. J., Santos, A., &, Hirsh, J., (1982) Sex related differences in platelet function: the effect of aspirin. Blood, 59 (3), 625-627.
23. Buchanan, M. R., Rischke, J. A., Butt, R., &, Turpie, A., (1983) The sex-related differences in aspirin pharmacokinetics in rabbits and man and its relationship to antiplatelet effects. Thrombosis Research, 29, 125-139.
24. Berger, J. S., Roncaglioni, M. C., &, Avanzini, F., (2006) Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA: The Journal of the American Medical Association, 295 (3), 306-313.
25. Ben-Dor, I., Kleiman, N. S., &, Lev, E., (2009) Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. American Journal of Cardiology, 104 (2), 227-233.
26. Greenblatt, D. J., Harmatz, J. S., Singh, N. N., et al. (2013) Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. Journal of Clinical Pharmacology, 54 (3), 282-290.
27. Contopoulos-Ioannidis, D. G., Ntzani, E. E., &, Ioannidis, J. P. A., (2003) Translation of highly promising basic science research into clinical applications. The American Journal of Medicine, 114 (6), 477-484.
28. IMS Institute for Healthcare Informatics (2012). The uses of medicine in the United States: review of 2011 [Internet]. Available at: http://www.imshealth.com/ims/Global/Content/Insights/IMS%20Institute%20for%20Healthcare%20Informatics/IHII-Medicines-in-U.S-Report-2011.pdf (last accessed 16 February 2014).
29. Evidence-Based Medicine Working Group (1992) Evidence-based medicine: a new approach to teaching the practice of medicine. JAMA: The Journal of the American Medical Association, 268 (17), 2420-2425.
30. Sackett, D. L., (1999) Time to put the Canadian Institutes of Health Research on trial. Canadian Medical Association Journal, 161 (11), 1414-1415.
31. Kuhn, T. S., (2012) The Structure of Scientific Revolutions, 4th edn. Chicago: University of Chicago Press.
32. Nowell, P. C., (1960) A minute chromosome in human chronic granulocytic leukemia. Science, 132, 1497.
33. Rowley, J. D., (1973) A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature, 243 (5405), 290-293.
34. Heisterkamp, N., Stephenson, J. R., Groffen, J., &, Hansen, P. F., (1983) Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature, 306, 239-242.
35. Shtivelman, E., Lifshitz, B., Gale, R. P., &, Canaani, E., (1985) Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature, 315, 550-554.
36. Lugo, T. G., Pendergast, A. M., Muller, A. J., &, Witte, O. N., (1990) Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science, 247 (4946), 1079-1082.
37. Daley, G. Q., Van Etten, R. A., &, Baltimore, D., (1990) Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science, 247 (4944), 824-830.
38. Druker, B. J., Tamura, S., Buchdunger, E., et al. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Medicine, 2 (5), 561-566.
39. Druker, B. J., Talpaz, M., Resta, D. J., et al. (2001) Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. The New England Journal of Medicine, 344 (14), 1031-1037.
40. O'Brien, S. G., Guilhot, F., Larson, R. A., et al. (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The New England Journal of Medicine, 348 (11), 994-1004.
41. Khoury, H. J., Cortes, J. E., Kantarjian, H. M., et al. (2012) Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure. Blood, 119 (15), 3403-3412.
42. Giacomini, M., (2009) Theory-based medicine and the role of evidence: why the emperor needs new clothes, again. Perspectives in Biology and Medicine, 52 (2), 234-251.
43. Worrall, J., (2008) Evidence and ethics in medicine. Perspectives in Biology and Medicine, 51 (3), 418-431.